73 Days
Source:
عربية – DW
Source: عربية – DW
73 Daysعربية – DW
Source: عربية – DW
73 DaysReady to play
Ready to play
Danish pharmaceutical company Novo Nordisk has launched the weight loss medication "Wegovy" in tablet form in Germany, making it the first market in the European Union where the drug is available as a dissolvable tablet. The move aims to compete with the increasingly popular weight loss products available in the market. The tablet contains the active ingredient semaglutide, previously used in injectable "Wegovy" and the diabetes medication "Ozempic." The cost of the tablets is estimated to range between 170 and 280 euros, depending on the dosage. The medication must be prescribed by a healthcare professional and used within the framework of a comprehensive treatment plan that includes a diet and ongoing physical activity, along with medical follow-up. It is important to note that obesity medications are considered part of a treatment for a chronic condition, not a magic solution. Novo Nordisk is competing with Eli Lilly, which has launched drugs such as "Zepbound" and "Fada" (Fondaio), highlighting a weight loss market expected to exceed $100 billion annually by 2030.
Notice: This Is an AI-Generated Summary
Comments (0)